Pulse Steroid Injection in Refractory Rheumatoid Arthritis

Revealing the Potential of Intravenous Pulse Steroid Therapy; Impressive Results in Attaining Remission or Low Disease Activity in Refractory Rheumatoid Arthritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06456489

Enrollment

268

Registered

2024-06-13

Start date

2024-05-01

Completion date

2024-12-31

Last updated

2024-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Rheumatoid Arthritis

Brief summary

Remission or low disease activity in active rheumatoid arthritis

Detailed description

Assessment of rheumatoid arthritis activity by Disease activity score DAS28, DAS28 Erythrocyte sedimentation rate (ESR), American college of rheumatology (ACR) 20, ACR 50, ACR 70 will be done at baseline and every month for 3 consecutive months for both groups.

Interventions

DRUGSolumedrol

125 mg methylprednisolone intravenous pulse on 2 consecutive days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Refractory rheumatoid arthritis patients

Exclusion criteria

* Other connective tissue diseases * Endocrine diseases such as DM and thyroid disorders

Design outcomes

Primary

Measure	Time frame	Description
remission or low disease activity	4 months	Outcome measurements for both groups will be done at baseline and every month for 3 months. DAS28, DAS28 ESR ACR20 ACR50 ACR70

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026